Spots Global Cancer Trial Database for Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
Official Title: Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
Study ID: NCT05717400
Conditions
Study Description
Brief Summary: To learn if giving immune checkpoint therapy (such as atezolizumab) and bevacizumab to patients who have HCC and are receiving DAAs may help to control HCC and hepatitis C.
Detailed Description: Primary Objective(s): * Estimate the objective response rate (ORR) to ICT and estimate the sustained virologic response (SVR) in patients with HCC and chronic HCV infection using HCV clearance with DAA therapy. * Estimate the change of the overall T cells and virus-specific T cells before and after the antiviral treatment in patients with HCC and chronic HCV infection using HCV clearance with DAA therapy. Secondary objective: --Collect the safety profile of the treatment and estimate the time-to-event variable such as overall survival (OS) and progression free survival (PFS).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Harrys A. Torres, MD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
